Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10918381 | Radiotherapy and Oncology | 2014 | 10 Pages |
Abstract
Although the importance of epigenetic alterations is widely accepted, their application as biomarkers in radiotherapy has not been studied extensively. In addition, it has been suggested that radiotherapy itself introduces epigenetic alterations. As epigenetic alterations can potentially be reversed by drug treatment, they are interesting candidate targets for anticancer therapy or radiotherapy sensitizers. The application of demethylating drugs or histone deacetylase inhibitors to sensitize patients for radiotherapy has been studied in vitro, in vivo as well as in clinical trials with promising results. This review describes the current knowledge on epigenetics in radiotherapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Kim M. Smits, Veerle Melotte, Hanneke E.C. Niessen, Ludwig Dubois, Cary Oberije, Esther G.C. Troost, Maud H.W. Starmans, Paul C. Boutros, Marc Vooijs, Manon van Engeland, Philippe Lambin,